Citations

Clear

112 citation(s) found for "Schaefer, PL".

Optimizing Recovery After Meniscal Repair: Standard Versus Complex Rehabilitation Pathways
Schaefer, Jacob J. , Hevesi, Mario , Krych, Aaron J. , Krych, Aaron J , Hevesi, Mario

Mayo Clinic

Arthroscopy | September 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/arj.70589 Get It

Abstract Meniscus surgery remains one of the most common orthopedic procedures worldwide. Successful meniscus repair requires A natomic reduction, B iologic preparation and augmentation, C ircumferential compression (ABCs), and an optimized rehabilitation protocol. Rehabilitation after surgery is critical for optimizing outcomes, yet the ideal approach remains controversial. A recent international European Union‐United States consensus task force developed recommendations for rehabilitation meniscal surgery. The group concluded that rehabilitation after meniscal repair and reconstruction should progress according to both time‐ and criterion‐based milestones. In practice, 2 rehabilitation pathways are utilized after meniscal repair: a standard protocol for biomechanically stable repairs that tolerate some weight‐bearing in full extension and a complex protocol for repairs requiring greater protection. Standard meniscal repairs (i.e., vertical longitudinal) are biomechanically stable and treated with moderate protection. During the first 4 weeks, patients are restricted to 0° to 90° of knee range of motion, partial weight‐bearing with crutches, and full knee extension during ambulation. Between weeks 4 and 8, patients progress to weight‐bearing as tolerated while avoiding loaded knee flexion beyond 90° until week 16, with emphasis on gait normalization and strengthening. From weeks 8 to 16, aerobic conditioning and strengthening continue. Pending surgeon clearance, return to running begins at week 12, plyometric exercises at week 14, and return to sport at 4 to 8 months. Complex meniscal repairs (e.g., radial or root tears) require a protective rehabilitation approach. During weeks 0 to 6, range of motion is restricted to 0° to 90° with toe‐touch weight‐bearing and full knee extension during ambulation. Range of motion and weight‐bearing progress from weeks 6 to 12, while loaded flexion beyond 90° remains restricted until week 16. Between weeks 12 and 18, aerobic conditioning and strengthening continue. Pending surgeon clearance, running begins at week 14, plyometrics at week 16, and return to sport typically occurs at 6 to 9 months.
Interleukin-17A mediates cardiorenal injury in oxalate nephropathy
Wimmer, Moritz I. , Reichel, Martin , Thiele, Arne , Yarritu, Alex , Rauch, Ariana , Anandakumar, Harithaa , Goetz, Luisa Hernandez , Lesker, Till Robin , Potapenko, Olena , Gebremedhin, Natnael , Anders, W , Contreras, Sarah V. Liévano , Höppe, Bernd , Schiattarella, Gabriele G. , Holle, Johannes , Knauf, Felix , Wilck, Nicola , Bartolomaeus, Hendrik , Hernández Götz, Luisa , Lesker, Till R , Anders, Wibke , Liévano Contreras, Sarah V , Wang, Rongling , Behrens, Felix , Hoppe, Bernd , Nonn, Olivia , Schiattarella, Gabriele G. , Schaefer, Franz , Holle, Johannes , Strowig, Till , Zernecke, Alma , Eckardt, Kai-Uwe , Knauf, Felix , Wilck, Nicola , Bartolomaeus, Hendrik , Potapenko, Olena

Mayo Clinic

Cardiovascular Research | July 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/cvr/cvag158 | PMID 42417540 Get It

Abstract Aims Cardiovascular disease (CVD) is the leading cause of mortality in chronic kidney disease (CKD). While CKD is known to give rise to systemic inflammation, its inciting factors remain poorly defined. Oxalate, long implicated in rare genetic kidney disorders, accumulates with decreased kidney function and has emerged as a driver of inflammation and independent risk factor for CVD. Here, we investigate the immunological mechanisms linking oxalate nephropathy to systemic inflammation, cardiac damage and kidney injury. Methods and results Oxalate nephropathy was induced in C57BL6/N mice through an oxalate-enriched diet. Oxalate induced systemic immune activation, renal fibrosis, and adverse cardiac remodelling, including pulmonary congestion with systolic and diastolic dysfunction. Flow cytometry analysis identified interleukin (IL)-17A as a dominant inflammatory effector, with expansion of Th17 and Th17-like Treg in the kidney, intestine, and spleen. Bulk mRNA sequencing confirmed these findings in kidney and heart. In line, plasma IL-17A was increased in oxalate-fed mice. Confirming the oxalate-IL-17A relationship, plasma IL-17A was elevated in patients with primary hyperoxaluria. Gut microbiome analysis by 16S amplicon sequencing showed only mild oxalate-induced alterations in mice. However, soluble oxalate directly enhanced Th17 polarization and disrupted mitochondrial respiration in vitro. In vivo, antibody-mediated IL-17A blockade improved kidney function, cardiac fibrosis, reduced neutrophil infiltration, and partially restored cardiac function in oxalate-fed mice. Conclusion Our study identifies oxalate as a systemic immunometabolic stressor and IL-17A as a central mediator of oxalate-induced cardiorenal injury. These findings establish the oxalate-IL-17A axis as a mechanistic link between CKD and CVD and suggest IL-17A inhibition as a potential therapeutic strategy to reduce cardiovascular damage in CKD.
Reversible White Matter Diffusion Restriction Lesion in Pediatric Cerebral Malaria
Lai, Sammie , Taskin, Didem, Hana, Leticia Schaefer Abu, Kim, Jeong-A, Schaefer Abu Hana, Leticia

Mayo Clinic

Neurology | June 18, 2026 | Volume: 107 | Issue: 2 | Pages: No page available

10.1212/wnl.0000000000218221 | PMID 42314079 Get It

Cerebellar Tonsillar Ectopia: Navigating Intracranial Hypertension and Hypotension in a Child (P6-15.007)
Lai, Sammie , Nguyen, Sarah, Pandya, Jay, Taskin, Didem, Hana, Leticia Schaefer-Abu, Shah, Chetan, Kim, Jeong-A

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215128 Get It

AAPM Task Group Report 336: Quality assurance for 3D printing in medical imaging and radiation therapy applications
Leng, Shuai, Craft, D. , Angel, Erin , Howell, Rebecca M., Jesseph, F., Kiarashi, Nooshin, Lewis, John H., Lo, Joseph, Markovic, Alex, McGee, Kiaran P. , Prah, D.E. , Rasmussen, Karl H., Rong, Yi, Schaefer, Kyle E., Solomon, Justin B., Leng, Shuai , Howell, Rebecca M. , Ionita, Ciprian N. , Lewis, John Henry , Lo, Joseph Yuan-Chieh , Solomon, Justin , Wake, Nicole

Mayo Clinic

Medical Physics | April 29, 2026 | Volume: 53 | Issue: 5 | Pages: No page available

10.1002/mp.70446 Get It

Abstract Additive manufacturing (AM), commonly referred to as 3D printing, has been broadly used in the field of medical imaging and radiotherapy. In medical imaging applications, patient‐specific anatomic models have been used to aid in preoperative planning, patient communication, imaging technique assessment and optimization, and medical education. Within the field of radiation therapy, 3D printing finds significance in fabricating patient‐specific immobilization devices, custom bolus devices, anthropomorphic phantoms, brachytherapy devices, and electron therapy devices. Consistent with standard medical physics practices there is a need to establish quality assurance and quality control (QA/QC) protocols, tolerances, and testing frequencies. The diversity of 3D printing technologies and products poses challenges for medical adoption and thus requires guidelines in workflow standardization and establishment of testing procedures. This report is centered around providing comprehensive vendor‐neutral implementation guidelines and recommendations for QC and QA processes. The scope of this report encompasses diverse requirements within medical imaging and radiation therapy settings, serving both clinical and research purposes. Brief overview of 3D printing technology, common materials, and potential clinical applications is provided. QA team, infrastructure, measurement techniques and challenges are discussed. QA processes for each step in 3D printing are discussed in great detail and baseline and action limits are recommended. This report also touched on regulatory considerations. Key recommendations are summarized at the end of the report.
Return-to-Sport Rates and Functional Outcomes After Hip Arthroscopy for Femoroacetabular Impingement in Young Football Athletes: A 9.8-Year Follow-up
Schaefer, Jacob J. , Kang, Louis , Ward, Gavin H. , Graden, Nathan R. , Levy, Bruce A., Hevesi, Mario, Krych, Aaron J., Okoroha, Kelechi R. , Krych, Aaron J. , Hevesi, Mario , Kang, Louis S , Hevesi, Mario , Krych, Aaron J , Levy, Bruce A.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | March 11, 2026 | Volume: 14 | Issue: 3 | Pages: No page available

10.1177/23259671261419484 | PMID 41815515 Get It

Background: Frequent pivoting, rotation, and deep hip flexion place football players at high risk for femoroacetabular impingement (FAI), a leading cause of hip pain in this population. Previous studies have primarily focused on professional National Football League athletes undergoing mixed surgical techniques, including labral debridement. Limited data exist on outcomes in younger, amateur players treated with labral repair. Purpose: To report return to sport (RTS) rates and functional outcomes at a minimum 5-year follow-up in primarily active high school and college football players undergoing primary hip arthroscopy with labral repair for FAI. Study Design: Case series, Level of evidence, 4. Methods: All football players who underwent primary hip arthroscopy with labral repair for FAI between 2010 and 2019 were identified from an institutional database. Collected data included descriptive data, radiographic parameters, surgical details, and reoperations. At a minimum 5-year follow-up, RTS outcomes and patient-reported outcome measures (PROMs), such as the Modified Harris Hip Score (mHHS) and Hip Outcome Score (HOS), were evaluated. Results: A total of 36 hips in 27 male athletes (mean age, 18 years; body mass index, 28.1 kg/m 2 ) were included. The majority of athletes competed at the high school (70%) or collegiate level (26%). Mean preoperative radiographic measurements were as follows: lateral center-edge angle, 31.6°; Tönnis angle, 4.1°; and alpha angle, 61.4°. Femoroplasty and acetabuloplasty were performed in 100% and 86% of cases, respectively. Also, 84% of players returned to football, all at the same or higher level than before surgery. At a mean follow-up of 9.8 years, all PROMs improved significantly from baseline ( P < .002). Outcome scores at follow-up were as follows: mHHS 90.5; HOS-Activities of Daily Living, 94.5; HOS-Sports-Specific Subscale, 91.1; and visual analog scale (VAS) pain with use, 2.3/10; VAS pain at rest, 1.3/10; and surgical satisfaction, 8.5/10. No patients required revision surgery. However, 2 patients (7%) underwent reoperations—including 1 for heterotopic ossification excision and 1 for periacetabular osteotomy. Conclusion: American football players who underwent primary hip arthroscopy with labral repair for FAI achieved excellent long-term outcomes, with high RTS rates at the same or higher levels, and improvements in PROMs and patient satisfaction. Despite favorable outcomes, nonmedical factors, such as graduation, may influence RTS in competitive athletes, particularly at the high school and collegiate levels.
Transport vehicle–mediated TREM2 PET maps myeloid cells in the glioblastoma microenvironment
Brendel, M., Feng, Ruoqing, Mueller, Katharina, Kössinger, Anna Laura, Teske, Nina C. , Greve, Thomas, Kirchleitner, Sabrina Viktoria, Nikolaishvili, Elene, Lorenz, Julia , Hoermann, Leonie , Kunze, Lea H. , Schaefer, Rebecca , Liu, Lu , Haertel, Marlies, Dhoqina, Dario , Gnörich, Johannes, Turhan, Sena Gül, Ertürk, Ali, Thevis, Justus Flinn, Park, Ha Eun, Wind, Karin , Lindheimer, Felix, Zenatti, Valerio , Prestel, Matthias , Lichtenthaler, Stefan, Werner, Rudolf, Riemenschneider, Markus, Kalasauskas, Darius , Schmutzer-Sondergeld, Michael, Stoecklein, Veit M. , Ringel, Florian , Meyer, Ana-Claire, Lewcock, Joseph W. , Monroe, Kathryn M. , Schlepckow, Kai , Haass, Christian, Herms, Jochen , Albert, Nathalie L. , Brendel, Matthias , Bartos, Laura M. , Mueller, K , Koessinger, Anna L. , Kirchleitner, Sabrina Viktoria , Blobner, Jens , Gnörich, Johannes , Müller, Stephan A. , Kolabas, Zeynep Ilgin , Ulukaya, Selin , Ertürk, Ali , Lindheimer, Felix , Bhat, Krishna , Tahirović, Sabina , Lichtenthaler, Stefan F. , Schmutzer-Sondergeld, Michael , Meyer, Ana-Claire, Haass, Christian , Baumgarten, Louisa von , Harter, Patrick N. , Simons, Mikael , Lindner, Simon

Mayo Clinic

No container title available | February 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8627080/v1 Get It

Abstract Glioblastomas exhibit low immunogenicity and a highly immunosuppressive tumor microenvironment (TME) mediated by both tumor cells and tumor associated microglia/macrophages (TAMs). However, biomarkers that allow for specific detection, monitoring and therapy response assessment of the TAM phenotype in glioblastoma are still lacking. To address this gap, we characterized the dynamics of TAM clusters in the TME of experimental SB28 glioblastoma using single-cell RNA sequencing, immunofluorescence, and molecular imaging and identified Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) as a dynamic TAM-specific target. Consequently, we investigated a novel 64 Cu-labeled TREM2 radiotracer with a blood-brain barrier transport vehicle for translational mapping of TAMs in the TME of glioblastoma. We found strong and highly myeloid cell-specific PET signals that followed the trajectory of TREM2 gene expression from early- towards late-stage tumors. Transient myeloid cell depletion via CSF1R inhibition showed a reduction of TREM2 PET signals compared to placebo and prolonged survival in SB28 glioblastoma mice, while TREM2 stimulation led to increased TREM2 PET signals. Translation into a pilot cohort of patients with glioblastoma revealed strong TREM2 PET signals predominantly at lesion edges and high heterogeneity across individuals, matching with immunohistochemistry. In summary, TREM2 PET imaging has strong potential as an immune cell-specific biomarker for personalized assessment of the TAM phenotype in the TME of patients with glioblastoma.
Functional genomics identifies therapeutic options, biomarkers, and resistance mechanisms for high-grade gliomas
Lin, Wan-Hsin, Kosari, Farhad , Smadbeck, James B. , Barrett, Michael T. , Feathers, Ryan, Hall, Jamie, Sadeghian, Dorsay , Johnson, Sarah H. , Harris, Faye R. , Berry, Taylor, McCune, Alexa, Murphy, Stephen James, Kinsella, Lindsey, Ensign, Shannon P. Fortin, Yang, Lin , Emanuel, Angela, Jones, Leila A., Schaefer-Klein, Janet, Ida, Cristiane M., Sherman, Wendy, Porter, Alyx B. , Rosenfeld, Steven, Kizilbash, Sani H., Jaeckle, Kurt A. , Mrugala, Maciej M., Borad, Mitesh, Bendok, Bernard R., Quiñones-Hinojosa, A., Cheville, John C. , Vasmatzis, George , Anastasiadis, Panos Z. , Ensign, Shannon P. Fortin , Mansfield, Aaron S , Ensign, Shannon P. Fortin , Sotiriou, Sotiris , Haydu, Lauren E. , Moniz‐Garcia, Diogo , Ida, Cristiane M., Salomao, Marcela , Kizilbash, Sani H. , Mrugala, Maciej M., Mansfield, Aaron S. , Borad, Mitesh J. , Bendok, Bernard R. , Burns, Terry C. , Quiñones‐Hinojosa, Alfredo

Mayo Clinic

No container title available | February 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.01.701806 | PMID 41676502 Get It

Abstract High-grade gliomas (HGGs) are aggressive tumors with poor outcomes and limited treatment options. Here, we combined genomic and transcriptomic tumor profiling with drug testing in a patient-derived 3-dimensional culture model to identify individualized treatments and predictive biomarkers. Activity of single agents targeting frequently dysregulated glioma pathways was relatively poor ex vivo and generally reflected historical patient data. However, compounds targeting PI3K, epigenetic, and survival/senescence signaling were effective in some cases. Drug sensitivity correlated with transcriptional rather than genomic features and suggested heterogeneity as a resistance mechanism. Bromodomain and extraterminal domain inhibition was particularly effective in tumors enriched in the mesenchymal transcriptional subtype, promoted proneural transition, and was overcome by upregulated PI3K signaling. Notably, combinations were largely effective, with 6 strategies exhibiting stronger efficacy than corresponding single agents in most cases (58-77%). This study identifies HGG vulnerabilities and associated biomarkers, resistance mechanisms, and effective combination strategies that warrant further clinical validation. Graphical Abstract
Addition of Phentermine‐Topiramate to a Digitally Enhanced Lifestyle Intervention: A Double‐Blind Randomized Clinical Trial
Campos, Alejandro , Ghusn, Wissam , Cifuentes, Lizeth , Sacoto, Daniel Hernan, Fansa, Sima , Añazco, Diego , Ricardo‐Silgado, Maria L., Harmsen, W.L., Gunn, Heather J., Peterson, Craig, Larsen, Deborah, Varghese, Santosh T. , Hurtado, M D, Acosta, Andres, Campos, Alejandro , Ghusn, Wissam , Sacoto, Daniel , Hashem, Anas , Schaefer, Megan, Gunn, Heather , Hurtado, Maria Daniela , Acosta, Andres , Anazco, Diego , Ricardo-Silgado, Maria Laura , Schaefer, Megan, Gunn, Heather

Mayo Clinic

Obesity | January 21, 2026 | Volume: 34 | Issue: 3 | Pages: 524-536

10.1002/oby.70108 | PMID 41562388 Get It

ABSTRACT Objective This study compared the effects of phentermine‐topiramate‐ER (mid‐dose 7.5/46 mg) versus placebo on weight loss and cardiovascular disease (CVD) risk outcomes when used as an adjunct to a digitally enhanced lifestyle intervention (DELI). Methods We conducted a 12‐month, randomized, double‐blind, placebo‐controlled trial at a single tertiary academic center in the United States (June 2020–June 2022). Eighty participants with obesity (BMI ≥ 30 kg/m 2 ) were enrolled in the DELI program, consisting of in‐person and telehealth modalities, dietary and physical activity goals, and use of a smartphone application integrated with digital devices (Apple Watch and Bluetooth‐enabled weight scale and blood pressure monitor). Participants were randomized 1:1 to receive either phentermine‐topiramate‐ER ( n = 42) or placebo ( n = 38) in addition to the DELI. Results At 3 months, the phentermine‐topiramate group lost a mean of 10.82 kg versus 4.04 kg in the placebo group (mean difference −6.78 kg; p = 0.002). At 12 months, weight loss was 15.32 kg versus 5.85 kg, respectively (mean difference −9.48 kg; p < 0.001). Participants receiving phentermine‐topiramate‐ER experienced a 3.35% reduction in the estimated atherosclerotic CVD risk compared to baseline ( p = 0.004). Conclusions Phentermine‐topiramate‐ER, when combined with a DELI, produced significant and sustained weight loss and reduced CVD risk in adults with obesity. Trial Registration ClinicalTrials.gov : NCT04408586
The E-AHPBA—ESSO—Innsbruck consensus recommendations on peri- and postoperative management following liver resection
Maier, Eva , Stättner, Stefan, Carrión-Álvarez, Lucía , Martino, Marcello Di, Primavesi, Florian, Sochorová, Dana , Laarhoven, Stijn van , Balakrishnan, Anita, Buis, Carlijn I. , Cipriani, Federica, Erdmann, Joris, Frampton, A., Fuks, David, Melloul, Emmanuel, Oberkofler, Christian E. , Petritsch, Stefan, Raab, Helmut, Rahbari, Nuh N. , Rappold, Daniela , Ruzzenente, Andrea, Schäfer, Benedikt , Serrablo, Alejandro, Soreide, Kjetil, Ernesto, Sparrelid, Starlinger, Patrick P, Tinguely, Pascale, Dasari, Bobby V M, Donadon, Matteo, Dopazo, Cristina, Gruenberger, T., Jonas, E G, Malik, Hassan, Siriwardena, Ajith K, Braunwarth, Eva , Di Martino, Marcello , Olthof, Pim , van Laarhoven, Stijn , Cipriani, Federica , Erdmann, Joris I , Lancellotti, Francesco , Oberkofler, Christian , Sallinen, Ville , Søreide, Kjetil , Starlinger, Patrick , Aldrighetti, Luca , Donadon, Matteo , Dopazo, Cristina , Gruenberger, Thomas , Viganó, Luca , Maglione, Manuel , Stättner, Stefan , Primavesi, Florian , Breitkopf, Robert , Fuks, David , Gilg, Stefan , Gulla, Aistė , Margreiter, Christian , Reiberger, Thomas , Ruzzenente, Andrea , Schaefer, Benedikt, Schnitzbauer, Andreas A. , Søreide, Kjetil , Sparrelid, Ernesto , Starlinger, Patrick , Stavrou, Gregor Alexander , Aldrighetti, Luca , Dasari, B. , Gruenberger, Thomas , Jonas, Eduard , Malik, Hassan , Siriwardena, Ajith K. , Maglione, Manuel

Mayo Clinic

British Journal of Surgery | December 30, 2025 | Volume: 113 | Issue: 1 | Pages: No page available

10.1093/bjs/znaf272 | PMID 41467576 Get It

Abstract Background Liver surgery carries a high risk of complications due to the complex interplay of patient-related factors, disease characteristics, and liver function. Expertise is essential for healthcare professionals managing hepatobiliary patients. This European consensus provides evidence-based guidance on selected aspects of peri- and postoperative care. Methods A modified Delphi process was used to achieve consensus, with a 70% agreement threshold. The expert panel comprised hepatobiliary surgeons, anaesthetists, hepatologists, a specialist nurse, and a physiotherapist. A systematic literature search was conducted in PubMed/MEDLINE, Embase, Web of Science, and Cochrane databases. Six topics were addressed: thromboprophylaxis; perioperative antibiotics; prehabilitation/nutrition/mobilization; bile leak including bilioenteric anastomosis leaks; post-hepatectomy haemorrhage; and post-hepatectomy liver failure (PHLF). Evidence appraisal and statement development followed Scottish Intercollegiate Guidelines Network methodology. A patient representative reviewed the guideline. Results Searching the literature yielded 204 included publications from an initial 6514. Thirty-two statements were formulated with a median evidence level of 2. Evidence strength varied by topic with noticeably lower evidence levels in complex surgery settings and less prevalent conditions. In some topics, study heterogeneity and specific inclusion criteria resulted in conditional recommendations, despite high-level evidence. Notably, the weakest evidence was found for perioperative thromboprophylaxis and PHLF management. Strong recommendations were formulated for prehabilitation, early postoperative mobilization, and avoidance of routine drain use. Several evidence gaps warranting multicentre studies were identified. Conclusion Optimizing peri- and postoperative care after liver resection remains challenging. Standardizing key practices and addressing evidence gaps through collaborative research are vital to improve outcomes.